Literature DB >> 21221090

Can cancer clinical trials be fixed?

Malorye Allison.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21221090     DOI： 10.1038/nbt.1746

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  6 in total

1.  Avastin's commercial march suffers setback.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-09       Impact factor: 54.908

2.  Biomarker-led adaptive trial blazes a trail in breast cancer.

Authors:  Malorye Allison
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

3.  Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs?

Authors:  Elizabeth A Richey; E Alison Lyons; Jonathan R Nebeker; Veena Shankaran; June M McKoy; Thanh Ha Luu; Narissa Nonzee; Steven Trifilio; Oliver Sartor; Al B Benson; Kenneth R Carson; Beatrice J Edwards; Douglas Gilchrist-Scott; Timothy M Kuzel; Dennis W Raisch; Martin S Tallman; Dennis P West; Steven Hirschfeld; Antonio J Grillo-Lopez; Charles L Bennett
Journal:  J Clin Oncol       Date:  2009-07-27       Impact factor: 44.544

4.  Accelerated approval and oncology drug development timelines.

Authors:  Michael L Lanthier; Rajeshwari Sridhara; John R Johnson; Ann Farrell; Patricia Keegan; Robert Justice; Richard Pazdur
Journal:  J Clin Oncol       Date:  2010-03-01       Impact factor: 44.544

5.  Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Authors:  Manabu Soda; Young Lim Choi; Munehiro Enomoto; Shuji Takada; Yoshihiro Yamashita; Shunpei Ishikawa; Shin-ichiro Fujiwara; Hideki Watanabe; Kentaro Kurashina; Hisashi Hatanaka; Masashi Bando; Shoji Ohno; Yuichi Ishikawa; Hiroyuki Aburatani; Toshiro Niki; Yasunori Sohara; Yukihiko Sugiyama; Hiroyuki Mano
Journal:  Nature       Date:  2007-07-11       Impact factor: 49.962

6.  Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma.

Authors:  Gideon Bollag; Peter Hirth; James Tsai; Jiazhong Zhang; Prabha N Ibrahim; Hanna Cho; Wayne Spevak; Chao Zhang; Ying Zhang; Gaston Habets; Elizabeth A Burton; Bernice Wong; Garson Tsang; Brian L West; Ben Powell; Rafe Shellooe; Adhirai Marimuthu; Hoa Nguyen; Kam Y J Zhang; Dean R Artis; Joseph Schlessinger; Fei Su; Brian Higgins; Raman Iyer; Kurt D'Andrea; Astrid Koehler; Michael Stumm; Paul S Lin; Richard J Lee; Joseph Grippo; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Paul B Chapman; Keith T Flaherty; Xiaowei Xu; Katherine L Nathanson; Keith Nolop
Journal:  Nature       Date:  2010-09-30       Impact factor: 49.962
  6 in total
  1 in total

1.  Seattle Genetics rare cancer drug sails through accelerated approval.

Authors:  Laura DeFrancesco
Journal:  Nat Biotechnol       Date:  2011-10-13       Impact factor: 54.908
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.